tirzepatide mace FDA Says Compounded Must Exit the Market ESC 2025: Semaglutide cuts MACE

BPC-157, derived from a protein found in the stomach, has been extensively studied for its ability to accelerate the healing of tendons, ligaments, and muscles

Although GFAP remains widely used as a clinical marker of astrogliosis, it lacks the specificity required to distinguish maladaptive from adaptive astrocytic states, thereby limiting its diagnostic and prognostic utility

There was a reduced relative and absolute risk of MACE for semaglutide vs comparators across the entire continuum of CV risk

Alternative Treatment Options While GLP-1 medications can be helpful tools, it's important to understand the potential risks and side effects associated with these drugs